What's Happening?
Genentech, a subsidiary of Roche, has decided to terminate its partnership with Adaptive Biotechnologies, a collaboration initially valued at up to $2 billion. This partnership, formed in 2018 and announced in 2019, focused on developing T cell receptor (TCR)-based therapies for cancer. The decision to end the collaboration was disclosed in an SEC filing by Adaptive Biotechnologies, with the partnership officially concluding on February 9, 2026. Despite the termination, Adaptive will receive $33.7 million in non-cash revenue during the latter half of the year. The collaboration had previously achieved its first Investigational New Drug clearance in May 2023. Genentech's decision was not influenced by any emerging safety concerns, according to a spokesperson.
AD
Why It's Important?
The termination of this partnership marks a significant shift in the landscape of cancer therapy development, particularly in the field of TCR-based treatments. Adaptive Biotechnologies, which had been working on personalized cancer therapies, will now need to navigate the loss of a major partner and the associated resources. This development could impact the pace and scope of innovation in cancer treatment, potentially affecting patients who might benefit from these advanced therapies. The decision also reflects Roche's strategic retreat from TCR therapies, as evidenced by its discontinuation of related assets earlier in 2023.
What's Next?
Adaptive Biotechnologies will focus on winding down joint activities with Genentech and will no longer be bound by exclusivity obligations under the agreement. The company may seek new partnerships or avenues to continue its research and development in cancer therapies. Meanwhile, the broader industry may observe shifts in investment and focus areas, as companies reassess the viability and potential of TCR-based treatments.
